 |
Previous Article | Next Article 
The Journal of Neuroscience, March 1, 1998, 18(5):1913-1922
Presynaptic GABAB Autoreceptor Modulation of P/Q-Type
Calcium Channels and GABA Release in Rat Suprachiasmatic Nucleus
Neurons
Gong
Chen and
Anthony N.
van
den Pol
Department of Neurosurgery, Yale University Medical School, New
Haven, Connecticut 06520
 |
ABSTRACT |
GABA is the primary transmitter released by neurons of the
suprachiasmatic nucleus (SCN), the circadian clock in the brain. Whereas GABAB receptor agonists exert a significant effect
on circadian rhythms, the underlying mechanism by which
GABAB receptors act in the SCN has remained a mystery. We
found no GABAB receptor-mediated effect on slow potassium
conductance, membrane potential, or input resistance in SCN neurons
in vitro using whole-cell patch-clamp recording. In
contrast, the GABAB receptor agonist baclofen (1-100 µM) exerted a large and dose-dependent inhibition (up to
100%) of evoked IPSCs. Baclofen reduced the frequency of spontaneous IPSCs but showed little effect on the frequency or amplitude of miniature IPSCs in the presence of tetrodotoxin. The activation of
GABAB receptors did not modulate postsynaptic
GABAA receptor responses. The depression of GABA release by
GABAB autoreceptors appeared to be mediated primarily
through a modulation of presynaptic calcium channels. The baclofen
inhibition of both calcium currents and evoked IPSCs was greatly
reduced (up to 100%) by the P/Q-type calcium channel blocker agatoxin
IVB, suggesting that P/Q-type calcium channels are the major targets
involved in the modulation of GABA release. To a lesser degree, N-type
calcium channels were also involved. The inhibition of GABA release by
baclofen was abolished by a pretreatment with pertussis toxin (PTX),
whereas the inhibition of whole-cell calcium currents by baclofen was only partially depressed by PTX, suggesting that G-protein mechanisms involved in GABAB receptor modulation at the soma and axon
terminal may not be identical. We conclude that GABAB
receptor activation exerts a strong presynaptic inhibition of GABA
release in SCN neurons, primarily by modulating P/Q-type calcium
channels at axon terminals.
Key words:
GABA; GABAB receptor; suprachiasmatic
nucleus; circadian; neuromodulation; presynaptic; autapse; G-protein
 |
INTRODUCTION |
The suprachiasmatic nucleus (SCN) of
the hypothalamus acts as a circadian clock in the mammalian brain
(Moore and Eichler, 1972 ; Stephan and Zucker, 1972 ; for review, see van
den Pol and Dudek, 1993 ). The inhibitory amino acid transmitter GABA is
particularly important for SCN function. Most neurons here use GABA as
their primary transmitter (van den Pol and Tsujimoto, 1985 ; Moore and Speh, 1993 ). Half of all presynaptic boutons in the SCN contain GABA,
and all neurons studied ultrastructurally were postsynaptic to
GABAergic axons, partially arising from other SCN neurons (van den Pol,
1980 ; Decavel and van den Pol, 1990 ).
GABA receptors can be divided into two broad groups, one that is
coupled to Cl channels and is activated by GABA
and muscimol and blocked in most cases by the GABAA
antagonist bicuculline, and a second type that operates through
G-proteins and is activated by GABA and baclofen and blocked by
2-hydroxysaclofen (Bormann, 1988 ). GABAB receptors have
been studied in many other brain regions, most extensively in the
hippocampus. There GABAB receptors have both presynaptic
and postsynaptic actions (Dutar and Nicoll, 1988 ; Lambert and Wilson,
1993 ; Pitler and Alger, 1994 ). A substantial part of the mechanism of
GABAB receptor action in hippocampus and most other brain
regions is mediated by activation of K+ channels
through pertussis toxin-sensitive G-proteins (for review, see Gage,
1992 ; Bowery, 1993 ; Misgeld et al., 1995 ). Postsynaptic GABAB activation of K+ currents, often
leading to hyperpolarization, has been found in many parts of the brain
(for review, see Misgeld et al., 1995 ). GABAB receptors can
also modulate Ca2+ channels (Mintz and Bean, 1993 ;
Pfrieger et al., 1994 ; Diversé-Pierluissi et al., 1995 ; Dittman
and Regehr, 1996 ; Lambert and Wilson, 1996 ; Rhim et al., 1996 , Obrietan
and van den Pol, 1998 ) and thereby inhibit neurotransmission (Scholz
and Miller, 1991 ; Doze et al., 1995 ; Huston et al., 1995 ; Isaacson
and Hille, 1997 ).
Autoradiographic studies have shown GABAB receptor binding
in the SCN (Francois-Bellan et al., 1989 ). In parallel, a number of
studies have shown that GABA or GABAB receptor agonists
applied to the SCN phase shift circadian rhythms (Ralph and Menaker,
1989 ; Gannon et al. 1995 ; Gillespie et al., 1997 ). Despite the large body of evidence for GABAB actions relating to circadian
rhythms, all postsynaptic GABA responses could be completely blocked by the antagonist bicuculline, leading to the conclusion that
GABAA receptors probably account for all of the
postsynaptic actions of GABA in the SCN (Kim and Dudek, 1992 ). To
address the mystery of what mechanism GABAB actions in the
SCN might be operating through, we examined several questions in the
present study. If no postsynaptic GABAB-mediated slow IPSPs
can be detected, do presynaptic GABAB receptors act on axon
terminals? What is the ion channel target of GABAB actions?
Can G-protein blockers alter GABAB receptor actions?
To differentiate presynaptic from postsynaptic actions clearly, we used
cultures of SCN neurons consisting of either single self-innervating
neurons or multicellular synaptically coupled neurons. Previous work
has shown that SCN neurons in vitro demonstrate many of the
same actions that they do in vivo, including GABA release
and response to GABA (Chen and van den Pol, 1996 , 1997 ). Furthermore,
neurons in isolated SCN slices in vitro show circadian rhythms of activity (Inouye and Kawamura, 1979 ), and even single SCN
neurons in culture show circadian rhythms of electrical activity (Welsh
et al., 1995 ). Because of the robust presence of GABA, we tested the
hypothesis that GABA would have a potent presynaptic action
on GABAergic axons of SCN neurons.
 |
MATERIALS AND METHODS |
Cell culture. High-density multicell culture and
low-density microculture of SCN neurons were used and have been
described previously in detail (Chen and van den Pol, 1996 , 1997 ).
Briefly, the SCNs were dissected from brain slices containing optic
chiasm removed from postnatal pups (postnatal days 1 and 2) of Sprague Dawley rats. The tiny tissue blocks were incubated for 30 min in a
enzyme solution containing 10 U/ml papain, 0.5 mM EDTA, 1.5 mM CaCl2, and 0.2 mg/ml
L-cysteine. After washing the tissue twice with culture
medium, cells were dissociated by mechanical trituration and plated on
35 mm Petri dishes (Corning, Corning, NY). For multicell cultures, a
high density of cells (>20,000 cells/cm2) was
plated in the central area of culture dishes precoated with poly-D-lysine (0.3 mg/ml). For microcultures, a low density
of glial cells (~2000 cells/cm2) was first plated
on 35 mm Petri dishes. After 2-3 d of culture, 5 µM
cytosine arabinoside (ARA-C) was added into culture medium to arrest
the proliferation of glial cells. One to 2 d later, a low density
of neurons (3000 cells/cm2) was plated in dishes
containing microislands of glial cells (Furshpan et al., 1986 ; Bekkers
and Stevens, 1991 ; Johnson, 1994 ; Chen and van den Pol, 1996 , 1997 ).
After 1-2 weeks of culture, single neurons grown on microislands of
glial cells form synapses with themselves, and autaptic IPSCs can be
reliably evoked by depolarizing pulses (Chen and van den Pol, 1996 ,
1997 ). The culture medium contained minimal essential medium (Life
Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum
(Hyclone, Logan, UT) and serum extender (Collaborative Research,
Bedford, MA), 100 U/ml penicillin and streptomycin, and 6 g/l glucose. Two micromolar ARA-C was added 2 d after plating neurons. The cultures were maintained in an incubator at 37°C and 5%
CO2, and fed twice weekly.
Electrophysiology. Experimental procedures for whole-cell
voltage-clamp and current-clamp recordings have been detailed
previously (Chen and van den Pol, 1996 , 1997 ). In brief, a List EPC-7
amplifier interfaced with an Apple Macintosh computer was used to
acquire data with AxoData software. Axograph and Igor Pro software were used to analyze data. Data were sampled at 2-5 kHz and filtered at 1 kHz by an eight pole Bessel filter (Frequency Devices). Micropipettes were pulled from thin-wall borosilicate glass (World Precision Instruments) using a Narishige vertical puller, with a tip diameter of
~2 µm. The pipette resistance was ~3 M after filling with the
pipette solution. The series resistance was monitored continuously by
application of a negative voltage pulse ( 10 mV, 30 msec), and
compensated by 40-70% with the amplifier. A brief depolarizing pulse
(70 mV, 2 msec) was used to evoke presynaptic GABA release in single
autaptic neurons, with a holding potential usually at 60 mV.
Postsynaptic GABA receptor responses were induced by a brief pressure
ejection of GABA (50 µM, 2-4 psi, 10 msec) through a
micropipette (2 µm tip diameter) under computer control with the use
of a Picospritzer (General Valve, Fairfield, NJ). The recording chamber
was perfused continuously (2 ml/min) with a bath solution containing
(in mM): 150 NaCl, 2.5 KCl, 2 CaCl2, 10 HEPES, and 10 glucose, pH 7.3. The pipette solution contained (in
mM): 145 KCl, 0.5 K4-EGTA, 10 HEPES, 4 Mg-ATP,
and 0.5 Na2-GTP, pH 7.3. For recording of whole-cell
Ca2+ currents, the bath solution contained (in
mM): 110 NaCl, 40 TEA-Cl, 2.5 KCl, 5 BaCl2, 10 HEPES, 10 glucose, and 1 µM
tetrodotoxin (TTX), pH 7.3; the pipette solution contained (in
mM): 145 CsCl, 2 Cs4-EGTA, 10 HEPES, 4 Mg-ATP,
and 0.5 Na2-GTP, pH 7.3. Drugs were applied through a
series of glass flow pipes (400 µm inner diameter) fed by gravity.
Experiments were done at room temperature (22°C).
Baclofen, GABA, ( )-bicuculline methiodide,
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), TTX, -conotoxin GVIA,
Mg-ATP, and Na2-GTP were purchased from Sigma (St. Louis,
MO); 2-hydroxysaclofen and nimodipine were from Research Biochemical
International (RBI, Natick, MA); agatoxin IVB (also known as agatoxin
TK, similar to agatoxin IVA) was from Peptide International; pertussis
toxin (PTX) was from Sigma and RBI. Nimodipine was dissolved in
methanol to 10 mM. The final concentration was 4 µM; the 0.04% methanol vehicle had no effect on
Ca2+ currents or transmitter release. Toxins were
dissolved in distilled water, aliquoted, and stored at 80°C.
 |
RESULTS |
GABAB receptor activation inhibits evoked IPSCs
The SCN contains primarily GABAergic neurons. GABAA
receptors mediating GABA neurotransmission in the SCN have been well
documented (for review, see van den Pol et al., 1996 ). However, the
function of GABAB receptors remains poorly understood. We
examined the possible function of GABAB receptors in SCN
cultures by applying the specific GABAB receptor agonist
baclofen. A profound inhibition of GABA neurotransmission by baclofen
was observed in a dose-dependent manner. In some neurons a complete
(100%) block was found with high concentrations (100 µM)
of baclofen. Figure 1 shows the action of
baclofen on evoked autaptic IPSCs. Figure 1, A and
B, shows a typical neuron in which baclofen at
concentrations of 1-100 µM potently inhibited the evoked
IPSCs in a dose-dependent manner. Figure 1C is a bar graph
showing the group data of baclofen reduction of evoked IPSCs at various
concentrations. The IC50 of baclofen was 5-10
µM.

View larger version (21K):
[in this window]
[in a new window]
|
Figure 1.
Baclofen dose-dependent inhibition of evoked GABA
release in a single autaptic SCN neuron. A, Traces
showing a dose-dependent inhibition of baclofen on evoked IPSCs.
B, Line graph illustrating the time course of baclofen
inhibition. C, Histogram showing the dose-dependent
inhibition of IPSC amplitude by baclofen. IC50 is between 5 and 10 µM.
|
|
To ensure that the baclofen inhibition on IPSCs was induced
specifically by activating GABAB receptors, a
GABAB receptor antagonist, 2-hydroxysaclofen, was used to
antagonize the baclofen effect. Figure
2, A and B,
demonstrates that the evoked IPSC was totally blocked by the
GABAA receptor antagonist bicuculline (30 µM). The GABAB receptor agonist baclofen (10 µM) inhibited the amplitude of the IPSC by ~50%. Bath
application of the GABAB receptor antagonist 2-hydroxysaclofen (500 µM) increased the amplitude of the
IPSC in this neuron. In the presence of 2-hydroxysaclofen, the baclofen inhibition of the IPSC amplitude was greatly reduced (from 50 to 12%).
After washing off 2-hydroxysaclofen, application of baclofen again
produced a large inhibition of IPSCs (50%). Similar experiments were
repeated in six neurons. Baclofen inhibition before and during 2-hydroxysaclofen was 46.3 ± 5.8 and 8.0 ± 2.3%
(n = 7), respectively, a difference that is
statistically significant (p < 0.01, t test), suggesting that the inhibition of baclofen on
evoked IPSCs was attributed to the specific activation of
GABAB receptors. The fact that application of
2-hydroxysaclofen increased the mean basal amplitude of synaptically
evoked IPSCs (9.3 ± 0.7%) suggests that GABAB
receptors were activated by synaptically released GABA transmitter, and
that the GABAB receptor may participate in a tonic
depression of GABA release.

View larger version (22K):
[in this window]
[in a new window]
|
Figure 2.
Baclofen inhibition of GABA release is
antagonized by 2-hydroxysaclofen. A, Traces show a total
elimination of IPSC by 30 µM bicuculline
(BIC) and a great reduction of IPSC by 5 µM baclofen. 2-Hydroxysaclofen (SAC)
at 500 µM slightly increased IPSCs and largely reduced
the baclofen inhibition of IPSC. B, Line graph shows a
repeatable inhibition of IPSCs by bicuculline and baclofen and the
antagonism of baclofen (BACL) effect by
2-hydroxysaclofen.
|
|
Baclofen inhibits GABA release through a presynaptic mechanism
The potent inhibition of baclofen on neurotransmission could
possibly be mediated at either presynaptic or postsynaptic sites. In
brain slices, GABAB receptor-mediated slow IPSPs were not
detected in the SCN (Kim and Dudek, 1992 ). To examine whether there is any GABAB receptor-mediated slow IPSPs or IPSCs in our SCN
cultures, antagonists for both GABAA and GABAB
receptors were used to differentiate fast and slow components. Figure
3 demonstrates the absence of postsynaptic GABAB receptor-mediated slow responses in
cultured SCN neurons, in agreement with brain slice experiments (Kim
and Dudek, 1992 ). Figure 3A illustrates that the
GABAA receptor antagonist bicuculline (30 µM)
totally blocked the evoked IPSC. Additional application of
GABAB receptor antagonist 2-hydroxysaclofen (500 µM) together with bicuculline had no further effect
(n = 4). The holding potential was maintained at 45
mV to facilitate the detection of GABAB receptor-mediated
slow responses by increasing the driving force. The effect of
GABAB receptor activation on membrane potential and
membrane conductance was further examined. Figure 3, B and C, demonstrates that application of baclofen (10 µM) under both voltage-clamp and current-clamp conditions
potently inhibited spontaneous IPSCs and IPSPs but had no effect on
the membrane current (n = 12) or membrane potential
(n = 4). The downward current injection-induced
hyperpolarizing potentials in Figure 3C remained constant
before and during baclofen application, indicating no membrane
conductance change induced by baclofen (n = 4).
Together, these results suggest that baclofen inhibits GABA
neurotransmission not through a postsynaptic mechanism but solely
through activation of presynaptic GABAB autoreceptors.

View larger version (29K):
[in this window]
[in a new window]
|
Figure 3.
No slow postsynaptic GABAB responses
in SCN neurons. A, Evoked autaptic IPSC was totally
abolished by 30 µM bicuculline (BIC). Applied together with bicuculline, 2-hydroxysaclofen
(SACL, 500 µM) induced no further change.
B, In voltage clamp, baclofen (20 µM)
greatly reduced spontaneous IPSCs but induced no change in baseline.
C, In current-clamp condition, baclofen (20 µM) had no effect on resting membrane potential. Current
injection-induced hyperpolarizing potentials were not affected by
baclofen, indicating no change in cell membrane conductance after
baclofen application.
|
|
For a direct demonstration of a presynaptic action of GABAB
receptors, we compared the effect of baclofen on presynaptically evoked
IPSCs with postsynaptic flow pipe GABA application-induced responses in
single self-innervating neurons. The box in Figure 4A illustrates the
experimental arrangement. Figure 4, A-C, demonstrates that
baclofen (5 µM) strongly inhibited the presynaptically
evoked IPSC but had little effect on the postsynaptic GABA response in the same neuron. Figure 4D is a line graph showing
the differential effect of baclofen on presynaptic and postsynaptic
responses of a single neuron. Grouped data from six neurons are
summarized in Figure 4E, demonstrating a significant
reduction of presynaptically evoked IPSCs (p < 0.001) by baclofen but no effect on postsynaptic GABA
application-induced responses (p > 0.5),
suggesting a specific action of baclofen on presynaptic GABA release
instead of a modulation of postsynaptic GABA receptors.

View larger version (24K):
[in this window]
[in a new window]
|
Figure 4.
GABAB receptors presynaptically
modulate GABA release as negative feedback autoreceptors.
A, Control trace showing presynaptically evoked IPSC and
micropipette GABA application induced postsynaptic response. The
box illustrates that a brief depolarizing pulse of the
recorded single autaptic neuron evoked presynaptic axon release, and
that a brief flow pipe GABA application onto the cell induced a
postsynaptic response. B, Responses in the presence of
baclofen (20 µM). C, Superimposed traces
showing a reduction in IPSC by baclofen but little effect on
postsynaptic GABA receptor responses. D, Line graph
illustrating differential effects of baclofen on presynaptic evoked
IPSC and postsynaptic GABA response. E, Bar graph of
group data showing specific baclofen inhibition of evoked IPSCs but no
inhibition of postsynaptic GABA responses.
|
|
To address further the mechanism of baclofen actions on GABA
neurotransmission, spontaneous IPSCs in the absence and presence of TTX
(1 µM) were examined. The glutamate receptor antagonist CNQX (10 µM) was routinely added to the bath solution,
and this eliminated glutamatergic EPSCs. Figure
5A1 illustrates that in the
normal bath solution without TTX there were many large IPSCs attributed
to the spontaneous firing of action potentials. Baclofen (10 µM) eliminated almost all of the large IPSCs, whereas
small IPSCs persisted. Figure 5A2 is an amplitude
distribution histogram (n = 4) demonstrating a
significant inhibition of large-amplitude IPSCs by baclofen
(white bar). The median amplitude of IPSCs before baclofen
was 59.2 pA (range, 5.2-4920 pA) and after baclofen was 35.6 pA
(range, 5.4-3343 pA). There is a significant difference between the
two amplitude distribution histograms before and after baclofen
application (p < 0.001, Kolmogorov-Smirnov
test). Figure 5B1 illustrates that in the presence of TTX (1 µM), baclofen (10 µM) had no remarkable
effect on miniature IPSCs (mIPSCs). This is supported by the amplitude
distribution histogram (n = 5) shown in Figure
5B2. Baclofen did not significantly alter the amplitude distribution histogram of mIPSCs (p > 0.2, Kolmogorov- Smirnov test). The median mIPSC amplitude before
baclofen was 33.0 pA (range, 5.1-130.9 pA) and after baclofen was 32.8 pA (range, 5.2-122.8 pA). The absence of an effect of baclofen on the
amplitude of mIPSCs provides further evidence that baclofen does not
modulate postsynaptic GABAA receptors. The substantial
inhibition of baclofen on action potential evoked-large IPSCs but
little effect on TTX resistant mIPSCs suggests that the baclofen
inhibition may be related to Ca2+ influx, possibly
through modulation of voltage-dependent Ca2+
channels.

View larger version (35K):
[in this window]
[in a new window]
|
Figure 5.
Differential inhibition of baclofen on action
potential-dependent large IPSCs and action potential-resistant
miniature IPSCs. A1,A2, Consecutive traces
(A1) and amplitude distribution histogram (A2) illustrating substantial baclofen inhibition of
large-amplitude IPSCs. B1,B2, Consecutive traces
(B1) and amplitude distribution histogram
(B2) showing little effect of baclofen on the amplitude of mIPSCs in the presence of TTX (no significant difference by Kolmogorov-Smirnov test). Note the different vertical scale bars between A1 and B1.
|
|
P/Q-type calcium channels are the major target of GABAB
receptor modulation
Whole-cell Ca2+ currents, using
Ba2+ as the carrier, were evoked by a depolarizing
pulse of 40 msec, 90 mV at a holding potential of 90 mV. Figure
6A illustrates that the
whole-cell Ca2+ currents were almost completely
blocked by 100 µM Cd (n = 3). In the same
neuron, baclofen (1 µM) also reversibly inhibited the
whole-cell Ca2+ current. Figure 6B
shows a dose-dependent inhibition of baclofen on whole-cell
Ca2+ currents. The IC50 of baclofen was
between 1 and 10 µM, the same range of the
IC50 of baclofen on evoked IPSCs (see Fig. 1).

View larger version (26K):
[in this window]
[in a new window]
|
Figure 6.
Baclofen dose-dependent inhibition of calcium
currents. A, Recording traces and line graph showing the
abolition of ICa by Cd and strong inhibition
of ICa by baclofen (10 µM) in
the same neuron. B, Traces and histogram showing
dose-dependent inhibition of ICa by
baclofen. IC50 is between 1 and 10 µM.
|
|
Multiple types of Ca2+ channels, including L-, N-,
P-, and Q-type, have been characterized in central and peripheral
neurons (Tsien et al., 1988 ; Bean, 1989 ; Llinas et al., 1992 ). To test the hypothesis that baclofen inhibits evoked IPSCs in SCN neurons by
modulating specific subtypes of Ca2+ channels,
selective Ca2+ channel blockers were used. Figure
7A illustrates that after application of the L-type Ca2+ channel blocker
nimodipine (4 µM) and N-type Ca2+
channel blocker conotoxin GVIA (2 µM), additional
application of baclofen (10 µM) inhibited the remaining
non-L/N Ca2+ currents. Similar results were found in
four of six neurons. In another two neurons, baclofen inhibition
disappeared after blocking N-type Ca2+ currents (see
Fig. 9). Figure 7B shows a parallel experiment testing the
effect of baclofen on evoked IPSCs in the presence of L- or N-type
Ca2+ channel blockers. Blocking L-type channels by
nimodipine (4 µM) had no effect on evoked IPSCs
(n = 3), indicating no participation of L-type channels
in synaptic GABA release in SCN neurons. The N-type channel blocker
conotoxin GVIA (2 µM) significantly reduced the evoked
IPSC, suggesting that N-type channels mediate GABA release in SCN
axons. After the reduction of IPSC amplitude by conotoxin GVIA (2 µM), application of baclofen (10 µM)
further inhibited the remaining IPSC, suggesting a target other than
N-type channels being involved in baclofen inhibition.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 7.
Baclofen modulation of non-L-, non-N-type calcium
currents. A, In the presence of 4 µM
nimodipine (blocking L-type ICa) and 2 µM conotoxin GVIA (CgTx, blocking N-type
ICa), baclofen (20 µM)
inhibited the remaining non-L, non-N ICa.
B, Baclofen (20 µM) inhibited IPSCs in the
presence of nimodipine or conotoxin GVIA. Nimodipine had no effect on
IPSCs.
|
|
Figure 8A demonstrates
that the remaining non-L/N Ca2+ current modulated by
baclofen in Figure 7A may be mediated by P/Q-type Ca2+ channels. In this representative neuron of five
tested, the baclofen inhibition of Ca2+ currents
disappeared after treatment with agatoxin IVB (500 nM, also
known as agatoxin TK), a specific blocker of P/Q-type channels (Teramoto et al., 1993 ), suggesting that the Ca2+
current component modulated by baclofen was a P/Q-type current. Figure
8B shows a parallel experiment of baclofen combined
with agatoxin IVB on evoked IPSCs (n = 5). Repeated
application of baclofen (10 µM) reversibly inhibited
IPSCs. After application of agatoxin IVB (500 nM), the
application of baclofen induced no inhibition, suggesting that the
agatoxin IVB sensitive P/Q-type Ca2+ channels are
the target of baclofen modulation.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 8.
Baclofen modulation of P/Q type calcium currents.
A, In the presence of 4 µM nimodipine,
baclofen (20 µM) inhibition of the remaining non-L
ICa disappeared after agatoxin IVB
(AgaTx, 500 nM) blockade of P/Q type
ICa. B, Repeatable inhibition
of IPSCs by baclofen (20 µM) disappeared after agatoxin
IVB (500 nM), blocking most of the IPSC.
|
|
Although P/Q-type Ca2+ channels appear to be the
major targets of baclofen modulation in many SCN neurons, N-type
Ca2+ channels may also be modulated. Figure
9A shows one example of two
neurons in which baclofen (10 µM) inhibition of
Ca2+ currents did not occur after blocking N-type
currents by conotoxin GVIA (2 µM), suggesting a direct
modulation of N-type channels by baclofen. In a parallel experiment of
evoked IPSCs combining baclofen with conotoxin GVIA as shown in Figure
9B, baclofen (10 µM) in the control condition
greatly reduced the IPSC amplitude from 2.9 to 0.7 nA, whereas after
application of conotoxin GVIA (2 µM), baclofen (10 µM) only reduced the IPSC from 1.5 to 0.7 nA, suggesting
that N-type channels are part of the target of baclofen modulation.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 9.
Baclofen modulation of N-type calcium currents.
A, In the presence of 4 µM nimodipine,
baclofen (20 µM) inhibition of the remaining non-L
ICa disappeared after 2 µM
conotoxin GVIA blocking of N-type ICa.
B, Baclofen (20 µM) inhibition of IPSCs
was greatly reduced in the presence of 2 µM conotoxin
GVIA.
|
|
Figure 10 summarizes the change of
baclofen inhibition of both Ca2+ currents and evoked
IPSCs before and after application of conotoxin GVIA and agatoxin IVB.
The average (n = 6) baclofen inhibition of
Ca2+ currents before conotoxin GVIA was 46.0 ± 6.2% and after conotoxin GVIA was 51.4 ± 10.4%, showing no
significant difference (paired t test, p > 0.3). Whereas no significant conotoxin GVIA inhibition of baclofen
actions was found in the group mean, two of the six neurons tested did
show a conotoxin GVIA-mediated block of the baclofen inhibition (Fig.
9A). In contrast to the N-type Ca2+
channel blocker, the P/Q channel blocker showed a substantial block of
the baclofen effect. The baclofen inhibition of Ca2+
currents before agatoxin IVB was 47.2 ± 4.1% and after agatoxin IVB was 11.4 ± 2.5%, showing a significant reduction
(n = 4; paired t test, p < 0.001). In parallel with the action on Ca2+
currents, the mean baclofen inhibition of evoked IPSCs before conotoxin
GVIA was 49.1 ± 6.1% and after conotoxin GVIA was 42.3 ± 6.6%, having no statistical significance (n = 5, paired t test, p > 0.2). However, the
baclofen inhibition of IPSCs before agatoxin IVB was 52.7 ± 7.9%
and after agatoxin IVB was 19.6 ± 5.8%, indicating that the P/Q
channel blocker mediated a significant reduction in the baclofen
inhibition of IPSCs (n = 7; paired t test,
p < 0.01).

View larger version (27K):
[in this window]
[in a new window]
|
Figure 10.
Reduction of baclofen inhibition after blocking
P/Q-type calcium channels. A, Comparison of baclofen
inhibition of calcium currents before and after conotoxin GVIA and
agatoxin IVB. Baclofen inhibition was significantly reduced by
application of agatoxin IVB (p < 0.001).
B, Comparison of baclofen inhibition of evoked IPSCs
before and after conotoxin GVIA and agatoxin IVB. Similar to calcium
currents, baclofen inhibition of IPSCs was also reduced by application
of agatoxin IVB (p < 0.01).
|
|
Together, these results demonstrate that baclofen strongly modulates
P/Q-type and in some cells N-type Ca2+ channels.
This inhibitory modulation may underlie the mechanism of baclofen
inhibition on GABA neurotransmission in the SCN.
Involvement of PTX-sensitive and -insensitive G-proteins
GABAB receptors may be coupled to G-proteins in many
central neurons (Gage, 1992 ; Misgeld et al., 1995 ). To determine
whether GABAB receptors in SCN neurons are linked to
PTX-sensitive G-proteins, SCN cultures were treated with PTX (300 ng/ml) for 48 hr before baclofen was tested. Surprisingly, we found a
differential effect of baclofen on evoked IPSCs and
Ca2+ currents after treatment of PTX. Figure
11, A-C, illustrates an example in which, in the same autaptic neuron, baclofen (10 µM) had no effect on evoked IPSCs but produced a
remarkable inhibition (45%) of Ca2+ currents. This
phenomenon was confirmed by using PTX from two different sources (Sigma
and RBI), and repeated in different cultures. Figure
11D summarizes data from 14 neurons after PTX
pretreatment, examining the differential baclofen effect on IPSCs and
Ca2+ currents. The inhibition of baclofen on evoked
IPSCs was clearly blocked by PTX pretreatment, suggesting that baclofen
modulation of synaptic GABA release, possibly by modulation of
presynaptic N- and P/Q-type Ca2+ channels, is
dependent on PTX-sensitive G-proteins. The baclofen inhibition of
whole-cell Ca2+ currents was reduced (from 50 to
25%) but not fully blocked after PTX pretreatment, indicating that
part of the baclofen modulation of Ca2+ currents may
be mediated by PTX-insensitive G-proteins.

View larger version (22K):
[in this window]
[in a new window]
|
Figure 11.
Differential G-protein mediation of baclofen
inhibition of GABA release and calcium currents. A-C,
Line graph (A) and recording traces (B,
C) illustrating a differential effect of baclofen (20 µM) on IPSCs and ICa in the
same autaptic neuron after treatment PTX. D, Bar graph
showing pooled data that PTX abolished the baclofen inhibition of IPSCs
but only partially reduced the baclofen inhibition of
ICa.
|
|
 |
DISCUSSION |
Although substantial effects of GABAB receptors on
phase shifts of circadian rhythms, general neuronal activity levels,
and c-Fos gene expression are found in the SCN (Ralph and Menaker, 1989 ; Colwell et al., 1993 ; Gannon et al., 1995 ; Gillespie et al.,
1997 ), specific actions of GABAB receptors were not
detected in electrophysiological studies (Kim and Dudek, 1992 ). Our
data suggest that this apparent mystery is not a real discrepancy but instead is caused by a substantial block of transmitter release from
presynaptic GABAB autoreceptors, rather than a postsynaptic GABAB receptor-mediated slow hyperpolarizing response found
in many other brain regions. The mechanism underlying the presynaptic modulation of GABA neurotransmission in SCN neurons appears to be
mediated by a strong inhibition of Ca2+ channels,
specifically the P/Q- and N-type channels.
Presynaptic action of GABAB receptors
In most other regions of the brain, GABAB receptors at
postsynaptic sites inhibit activity by increasing K+
conductance and thus hyperpolarizing the membrane potential, resulting
in slow IPSPs (Newberry and Nicoll, 1984 ; Gahwiler and Brown, 1985 ;
Stevens et al., 1985 ; Crunelli et al., 1988 ; Lacey et al., 1988 ;
Osmanovic and Shefner, 1988 ). In previous work examining the actions of
GABAB receptors in SCN slices, no slow IPSPs were found
(Kim and Dudek, 1992 ). Similarly, we detected no evidence of
GABAB-mediated membrane potential changes in SCN neurons.
However, in striking contrast to the lack of GABAB
inhibition of GABAA responses at the soma, we found
substantial GABAB-mediated inhibition in presynaptic SCN
axons that released GABA. Phase shifts of circadian rhythms regulated
by the SCN can be generated by GABAB agonists (Ralph and
Menaker, 1989 ; Gannon et al., 1995 ; Gillespie et al., 1997 ). Our data
suggest that the primary action of GABAB receptors in SCN
neurons may be to modulate GABA release from axon terminals; this
inhibiton of GABA release may be one possible cellular substrate that
plays a role in phase shifting.
Inhibition of calcium channels
GABAB receptors reduced Ca2+
currents in SCN neurons. The channel that showed the greatest response
to baclofen was the voltage-activated P/Q-type Ca2+
channel. This channel appeared to account for a substantial
Ca2+ current. This is the first demonstration of the
relative importance of the P/Q channel in SCN neurons. N-type channels
were also modulated by GABAB receptor activation. These
channels (P/Q and N) may mediate the primary Ca2+
influx in presynaptic axons required to trigger transmitter release. Blocking their actions with specific blockers substantially reduced the
actions of GABAB receptors, suggesting that
Ca2+ channels are the major effector of
GABAB receptor modulation.
GABAB modulation of SCN neurons can be compared with
hippocampal neurons, in which GABAB receptors have been
studied more extensively. The SCN primarily contains GABAergic
neurons, whereas the hippocampus contains both glutamatergic and
GABAergic neurons. In the hippocampus, GABAB receptors
modulate neurotransmission both presynaptically and postsynaptically
and modulate both K+ and Ca2+
channels (Dutar and Nicoll, 1988 ; Lambert and Wilson, 1993 ;
Pfrieger et al., 1994 ; Doze et al., 1995 ). In contrast in the SCN,
GABAB receptors modulate neurotransmission in a specific
presynaptic way and only modulate Ca2+ channels,
with little detectable effect on K+ channels (Kim
and Dudek, 1992 ; this study). In hippocampal glutamatergic neurons, the
miniature EPSCs in the presence of TTX were significantly affected by GABAB receptors (Scanziani et al., 1992 ;
Dittman and Regehr, 1996 ). However, in both hippocampal and SCN
GABAergic neurons, the miniature IPSCs were not modulated by
GABAB receptors (Doze et al., 1995 ; this study).
Furthermore, in both hippocampal and SCN inhibitory neurons,
GABAB receptors modulate both P/Q-type and N-type
Ca2+ channels, with a larger effect on P/Q-type
Ca2+ channels. Whether these shared common
properties of inhibitory hippocampal and SCN neurons can be extended to
other GABAergic central neurons needs further work.
Modulation of calcium channels underlying the inhibition of
GABA release
The present study demonstrates that the activation of
GABAB receptors inhibited both whole-cell
Ca2+ currents and presynaptic GABA release in SCN
neurons. GABAB receptors can influence
Ca2+ currents at the cell body and may modulate GABA
release from the presynaptic axon in a similar manner. This is
supported by several lines of evidence. First, baclofen inhibited both
evoked IPSCs and Ca2+ currents in a dose-dependent
manner. Second, baclofen strongly inhibited action potential-dependent
IPSCs in the absence of TTX but had little effect on miniature IPSCs in
the presence of TTX, suggesting that the release apparatus down-stream
of Ca2+ influx is not modulated (Dittman and Regehr,
1996 ). More direct evidence comes from the parallel experiments using a
combination of selective Ca2+ channel blockers
together with baclofen. Baclofen inhibition of IPSCs was largely
eliminated in the presence of Ca2+ channel blockers
-conotoxin GVIA and agatoxin IVB, indicating that
Ca2+ channels are probable mediators of
GABAB receptor modulation in presynaptic nerve
terminals.
Because it is difficult to measure Ca2+ currents
directly at the small SCN axon terminals, we measured
Ca2+ currents at the cell body. Although both the
cell body and axon terminals may express similar
Ca2+ channels, Ca2+ influx at the
terminal may not be the same as at the cell body. The channel density
and relative proportion of each specific type (L-, N-, P/Q-, and
R-type) may be different in the soma and axon terminals of the same
cell.
GABAB-related G-proteins
The actions of GABAB receptors on the presynaptic GABA
release were substantially blocked by PTX. In contrast, the actions of
GABAB receptors on the somatic Ca2+
channels were only partially blocked by PTX. This suggests that although somatic Ca2+ channels in the SCN can be
modulated by a PTX-sensitive GABAB action, there may be
additional mechanisms whereby PTX-insensitive G-proteins also play a
modulatory role in Ca2+ channels. Another
possibility is that a different response to PTX exists in somata and
presynaptic axons. A simplified scheme illustrating a differential
modulation of GABAB receptors on presynaptic and
postsynaptic Ca2+ channels is shown in Figure
12, in which presynaptic P/Q-type and
N-type channels are modulated by PTX-sensitive Gi and
G0 proteins, but postsynaptic Ca2+
channels (including P/Q-, N-, and L-type) are modulated by both PTX-sensitive and -insensitive G-proteins.

View larger version (27K):
[in this window]
[in a new window]
|
Figure 12.
Simplified diagram illustrating
G-protein-mediated presynaptic and postsynaptic GABAB
receptor (GABAB R) modulation of multiple-type calcium
channels.
|
|
Our data indicate that the GABAB autoreceptors
modulate presynaptic GABA release by activating PTX-sensitive
G-proteins. This is in contrast to one group of reports that found
little effect of PTX on GABAB actions in presynaptic axons
in hippocampal preparations (Dutar and Nicoll, 1988 ; Thompson and
Gahwiler, 1992 ) but similar to another group that found that PTX
blocked presynaptic effects of GABAB receptors on axon
terminals (Scholz and Miller, 1991 ; Pfrieger et al., 1994 ; Pitler and
Alger, 1994 ). These differences could be caused by multiple mechanisms
of GABAB actions in the hippocampus or to different
activational states of the GABAB receptor-second messenger
system in different preparations. One advantage of the single neuron
culture approach we used is that PTX has full access to all parts of
the neuron plasma membrane. The same may not be true when PTX or
related agents are injected into the brain or applied to brain slices
in which diffusion may be impeded by multiple layers of astrocytes that
surround axon terminals.
Functional implications
The modulation of intracellular Ca2+ may be
generally relevant to phase shifting and clock mechanisms. For
instance, in bulla, phase shifts of the circadian clock in the ocular
circadian pacemaker are blocked by Ca2+ channel
antagonists (Khalsa and Block, 1988 ). Similarly,
Ca2+ can modulate the circadian variation of
melatonin secretion in chick pineal cells (Nikaido and Takahashi,
1996 ). In previous work on the rat SCN in vitro,
intracellular Ca2+ was found to play a crucial role
in the maintenance of circadian rhythms of 2-deoxyglucose
utilization (Shibata et al., 1987 ). The participation of
GABAB receptors in modulating Ca2+
influx may allow GABA to modulate cytoplasmic Ca2+
levels, thereby potentially influence clock timing.
Previous studies have shown that GABAA and
GABAB receptors may both play important roles in the
phase-shifting actions of light on circadian rhythms (Ralph and
Menaker, 1989 ; Gannon et al., 1995 ; Gillespie et al., 1997 ). The
present study is the first to demonstrate a widespread and profound
action of GABAB receptors on SCN neurons themselves, and
that GABA released by axons of SCN neurons can act autosynaptically,
depressing further GABA release from the same axon terminal. Golgi
impregnation studies of SCN axons show substantial axon collaterals
within the nuclei (van den Pol, 1980 ). Although many SCN synapses are
surrounded by astrocytes that may inhibit free diffusion to other axon
terminals (van den Pol et al., 1992 ), in some cases GABA can diffuse
from an active axon to another nearby (Isaacson et al., 1993 ). Although the immediate action of GABA is inhibitory, the GABAB
receptor-mediated inhibition of GABA release could have a net positive
effect on local synaptic circuits by reducing inhibition.
A primary action of GABAB receptors in SCN neurons appears
to be the modulation of GABA release from axons, and this inhibition of
GABA release may be one cellular substrate influencing circadian phase
shifts.
 |
FOOTNOTES |
Received Oct. 2, 1997; revised Dec. 15, 1997; accepted Dec. 18, 1997.
This work was supported by National Institutes of Health Grants NS34887
and NS10174, the National Science Foundation, and the Air Force Office
of Scientific Research. We thank Drs. Anne Williamson, Karl Deisseroth,
and Erika Piedras-Renteria for helpful suggestions on this manuscript
and Dr. Y. Yang for technical help.
Correspondence should be addressed to Anthony van den Pol, Department
of Neurosurgery, Yale University School of Medicine, 333 Cedar Street,
New Haven, CT 06520.
Gong Chen's present address: Department of Molecular and Cellular
Physiology, Beckman Center, Stanford University Medical School,
Stanford, CA 94305.
 |
REFERENCES |
-
Bean BP
(1989)
Multiple types of calcium channels in heart muscle and neurons. Modulation by drugs and neurotransmitters.
Ann NY Acad Sci
560:334-345[Web of Science][Medline].
-
Bekkers JM,
Stevens CF
(1991)
Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture.
Proc Natl Acad Sci USA
88:7834-7838[Abstract/Free Full Text].
-
Bormann J
(1988)
Electrophysiology of GABAA and GABAB receptor subtypes.
Trends Neurosci
11:112-116[Web of Science][Medline].
-
Bowery NG
(1993)
GABAB receptor pharmacology.
Annu Rev Pharmacol Toxicol
33:109-147[Web of Science][Medline].
-
Chen G,
van den Pol AN
(1996)
Multiple NPY receptors coexist in pre- and postsynaptic sites: inhibition of GABA release in isolated self-innervating SCN neurons.
J Neurosci
16:7711-7724[Abstract/Free Full Text].
-
Chen G,
van den Pol AN
(1997)
Adenosine modulation of calcium currents and presynaptic inhibition of GABA release in suprachiasmatic and arcuate nucleus neurons.
J Neurophysiol
77:3035-3047[Abstract/Free Full Text].
-
Colwell CS,
Kaufman CM,
Menaker M
(1993)
Photic induction of Fos in the hamster suprachiasmatic nucleus is inhibited by baclofen but not by diazepam or bicucullin.
Neurosci Lett
163:177-181[Web of Science][Medline].
-
Crunelli V,
Haby M,
Jassik-Gerschenfeld D,
Leresche N,
Pirchio M
(1988)
Cl
- and K+-dependent inhibitory postsynaptic potentials evoked by.
J Physiol (Lond)
399:153-176[Abstract/Free Full Text]. -
Decavel C,
van den Pol AN
(1990)
GABA: a dominant neurotransmitter in the hypothalamus.
J Comp Neurol
302:1019-1037[Web of Science][Medline].
-
Dittman JS,
Regehr WG
(1996)
Contributions of calcium-dependent and calcium-independent mechanisms to presynaptic inhibition at a cerebellar synapse.
J Neurosci
16:1623-1633[Abstract/Free Full Text].
-
Diversé-Pierluissi M,
Remmers AE,
Neubig RR,
Dunlap K
(1997)
Novel form of crosstalk between G-protein and tyrosine kinase pathways.
Proc Natl Acad Sci USA
94:5417-5421[Abstract/Free Full Text].
-
Doze VA,
Cohen GA,
Madison DV
(1995)
Calcium channel involvement in GABAB receptor-mediated inhibition of GABA release in area CA1 of the rat hippocampus.
J Neurophysiol
74:43-53[Abstract/Free Full Text].
-
Dutar P,
Nicoll RA
(1988)
Pre- and postsynaptic GABAB receptors in the hippocampus have different pharmacological properties.
Neuron
1:585-591[Web of Science][Medline].
-
Francois-Bellan AM,
Segu L,
Hery M
(1989)
Regulation by estradiol of GABAA and GABAB binding sites in the diencephalon of the rat: an autoradiographic study.
Brain Res
503:144-147[Web of Science][Medline].
-
Furshpan EJ,
Landis SC,
Matsumoto SG,
Potter DD
(1986)
Synaptic functions in rat sympathetic neurons in microcultures. I. Secretion of norepinephrine and acetylcholine.
J Neurosci
6:1061-1079[Abstract].
-
Gage PW
(1992)
Activation and modulation of neuronal K+ channels by GABA.
Trends Neurosci
15:46-51[Web of Science][Medline].
-
Gahwiler BH,
Brown DA
(1985)
GABAB-receptor-activated K+ current in voltage-clamped CA3 pyramidal cells in hippocampal cultures.
Proc Natl Acad Sci USA
82:1558-1562[Abstract/Free Full Text].
-
Gannon RL,
Cato MJ,
Kelley KH,
Armstrong DL,
Rea MA
(1995)
GABAergic modulation of optic nerve-evoked field potentials in the rat suprachiasmatic nucleus.
Brain Res
694:264-270[Web of Science][Medline].
-
Gillespie CF,
Mintz EM,
Marvel CL,
Huhman KL,
Albers HE
(1997)
GABAA and GABAB agonists and antagonists alter the phase-shifting effects of light when microinjected into the suprachiasmatic region.
Brain Res
759:181-189[Web of Science][Medline].
-
Huston E,
Cullen GP,
Burley JR,
Dolphin AC
(1995)
The involvement of multiple calcium channel sub-types in glutamate release from cerebellar granule cells and its modulation by GABAB receptor activation.
Neuroscience
68:465-478[Web of Science][Medline].
-
Inouye ST,
Kawamura H
(1979)
Persistence of circadian rhythmicity in a mammalian hypothalamic "island" containing the suprachiasmatic nucleus.
Proc Natl Acad Sci USA
76:5962-5966[Abstract/Free Full Text].
-
Isaacson JS,
Hille B
(1997)
GABAB-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons.
Neuron
18:143-152[Web of Science][Medline].
-
Isaacson JS,
Solis JM,
Nicoll RA
(1993)
Local and diffuse synaptic actions of GABA in the hippocampus.
Neuron
10:165-175[Web of Science][Medline].
-
Johnson MD
(1994)
Synaptic glutamate release by postnatal rat serotonergic neurons in microculture.
Neuron
12:433-442[Web of Science][Medline].
-
Khalsa SB,
Block GD
(1988)
Calcium channels mediates phase shifts of Bulla circadian pacemaker.
J Comp Physiol [A]
164:195-206[Medline].
-
Kim YI,
Dudek FE
(1992)
Intracellular electrophysiological study of suprachiasmatic nucleus neurons in rodents: inhibitory synaptic mechanisms.
J Physiol (Lond)
458:247-260[Abstract/Free Full Text].
-
Lacey MG,
Mercuri NB,
North RA
(1988)
On the K+ conductance increase activated by GABAB and dopamine D2.
J Physiol (Lond)
401:437-453[Abstract/Free Full Text].
-
Lambert NA,
Wilson WA
(1993)
Discrimination of post- and presynaptic GABAB receptor-mediated responses by tetrahydroaminoacridine in area CA3 of the rat hippocampus.
J Neurophysiol
69:630-635[Abstract/Free Full Text].
-
Lambert NA,
Wilson WA
(1996)
High-threshold Ca2+ currents in rat hippocampal interneurones and their selective inhibition by activation of GABAB receptors.
J Physiol (Lond)
492:115-127[Abstract/Free Full Text].
-
Llinas R,
Sugimori M,
Hillman DE,
Cherksey B
(1992)
Distribution and functional significance of the P-type, voltage-dependent Ca2+ channels in the mammalian CNS.
Trends Neurosci
15:351-355[Web of Science][Medline].
-
Mintz IM,
Bean BP
(1993)
GABAB receptor inhibition of P-type Ca2+ channels in central neurons.
Neuron
10:889-898[Web of Science][Medline].
-
Misgeld U,
Bijak M,
Jarolimek W
(1995)
A physiological role for GABAB receptors and the effects of baclofen in the mammalian CNS.
Prog Neurobiol
46:423-462[Web of Science][Medline].
-
Moore RY,
Eichler VB
(1972)
Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat.
Brain Res
42:201-206[Web of Science][Medline].
-
Moore RY,
Speh JC
(1993)
GABA is the principal neurotransmitter of the circadian system.
Neurosci Lett
150:112-116[Web of Science][Medline].
-
Newberry NR,
Nicoll RA
(1984)
Direct hyperpolarizing action of baclofen on hippocampal pyramidal cells.
Nature
308:450-452[Medline].
-
Nikaido SS,
Takahashi JS
(1996)
Calcium modulates circadian variation in cAMP-stimulated melatonin in chick pineal cells.
Brain Res
716:1-10[Web of Science][Medline].
-
Obrietan K, van den Pol AN (1998) GABAB receptor
mediated inhibition of GABAA receptor calcium elevations in
developing hypothalamic neurons. J Neurophysiol, in press.
-
Osmanovic SS,
Shefner SA
(1988)
Baclofen increases the potassium conductance of rat locus coeruleus.
Brain Res
438:124-136[Web of Science][Medline].
-
Pfrieger FW,
Gottmann K,
Lux HD
(1994)
Kinetics of GABAB receptor-mediated inhibition of calcium currents and excitatory synaptic transmission in hippocampal neurons in vitro.
Neuron
12:97-107[Web of Science][Medline].
-
Pitler TA,
Alger BE
(1994)
Differences between presynaptic and postsynaptic GABAB mechanisms in rat hippocampal pyramidal cells.
J Neurophysiol
72:2317-2327[Abstract/Free Full Text].
-
Ralph MR,
Menaker M
(1989)
GABA regulation of circadian responses to light. I. Involvement of GABAA-benzodiazepine and GABAB receptors.
J Neurosci
9:2858-2865[Abstract].
-
Rhim H,
Toth PT,
Miller RJ
(1996)
Mechanism of inhibition of calcium channels in rat nucleus tractus solitarius by neurotransmitters.
Br J Pharmacol
118:1341-1350[Web of Science][Medline].
-
Scanziani M,
Capogna M,
Gahwiler BH,
Thompson SM
(1992)
Presynaptic inhibition of miniature excitatory synaptic currents by baclofen and adenosine in the hippocampus.
Neuron
9:919-927[Web of Science][Medline].
-
Scholz KP,
Miller RJ
(1991)
GABAB receptor-mediated inhibition of Ca currents and synaptic transmission in cultured rat hippocampal neurones.
J Physiol (Lond)
444:669-686[Abstract/Free Full Text].
-
Shibata S,
Newman GC,
Moore RY
(1987)
Effects of calcium ions on glucose utilization in the rat suprachiasmatic nucleus in vitro.
Brain Res
426:332-338[Web of Science][Medline].
-
Stephan FK,
Zucker I
(1972)
Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions.
Proc Natl Acad Sci USA
69:1583-1586[Abstract/Free Full Text].
-
Stevens DR,
Gallagher JP,
Shinnick-Gallagher P
(1985)
Further studies on the action of baclofen on neurons of the dorsolateral septal.
Brain Res
358:360-363[Web of Science][Medline].
-
Teramoto T,
Kuwada M,
Niidome T,
Sawada K,
Nishizawa Y,
Katayama K
(1993)
A novel peptide from funnel web spider venom, omega-Aga-TK, selectively blocks P-type calcium channels.
Biochem Biophys Res Commun
196:134-140[Web of Science][Medline].
-
Thompson SM,
Gahwiler BH
(1992)
Comparison of the actions of baclofen at pre- and postsynaptic receptors in the rat hippocampus in vitro.
J Physiol (Lond)
451:329-345[Abstract/Free Full Text].
-
Tsien RW,
Lipscombe D,
Madison DV,
Bley KR,
Fox AP
(1988)
Multiple types of neuronal calcium channels and their selective modulation.
Trends Neurosci
11:431-438[Web of Science][Medline].
-
van den Pol AN
(1980)
The hypothalamic suprachiasmatic nucleus of rat: intrinsic anatomy.
J Comp Neurol
191:661-702[Web of Science][Medline].
-
van den Pol AN,
Dudek FE
(1993)
Cellular communication in the circadian clock, the suprachiasmatic nucleus.
Neuroscience
56:793-811[Web of Science][Medline].
-
van den Pol AN,
Tsujimoto KL
(1985)
Neurotransmitters of the hypothalamic suprachiasmatic nucleus: immunocytochemical analysis of 25 neuronal antigens.
Neuroscience
15:1049-1086[Web of Science][Medline].
-
van den Pol AN,
Finkbeiner SM,
Cornell-Bell A
(1992)
Calcium excitability and oscillations in suprachiasmatic nucleus neurons and glia in vitro.
J Neurosci
12:2648-2664[Abstract].
-
van den Pol AN,
Strecker GJ,
Dudek FE
(1996)
Excitatory and inhibitory amino acids and synaptic transmission in the suprachiasmatic nucleus.
Prog Brain Res
111:41-56[Web of Science][Medline].
-
Welsh DK,
Logothetis DE,
Meister M,
Reppert SM
(1995)
Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms.
Neuron
14:697-706[Web of Science][Medline].
Copyright © 1998 Society for Neuroscience 0270-6474/98/1851913-10$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
S. J. Aton, J. E. Huettner, M. Straume, and E. D. Herzog
GABA and Gi/o differentially control circadian rhythms and synchrony in clock neurons
PNAS,
December 12, 2006;
103(50):
19188 - 19193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-W. Cheng, M.-C. Ku, C.-M. Ho, C.-Y. Chai, and C.-K. Su
GABAB-receptor-mediated suppression of sympathetic outflow from the spinal cord of neonatal rats
J Appl Physiol,
November 1, 2005;
99(5):
1658 - 1667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Giustizieri, G. Bernardi, N. B. Mercuri, and N. Berretta
Distinct Mechanisms of Presynaptic Inhibition at GABAergic Synapses of the Rat Substantia Nigra Pars Compacta
J Neurophysiol,
September 1, 2005;
94(3):
1992 - 2003.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Clark III, C. S. Sampair, P. Kofuji, A. Nath, and Jian. M. Ding
HIV protein, transactivator of transcription, alters circadian rhythms through the light entrainment pathway
Am J Physiol Regulatory Integrative Comp Physiol,
September 1, 2005;
289(3):
R656 - R662.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Lu, R. M. Burger, and E. W Rubel
GABAB Receptor Activation Modulates GABAA Receptor-Mediated Inhibition in Chicken Nucleus Magnocellularis Neurons
J Neurophysiol,
March 1, 2005;
93(3):
1429 - 1438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-B. Gao, P. K. Ghosh, and A. N. van den Pol
Neurons Synthesizing Melanin-Concentrating Hormone Identified by Selective Reporter Gene Expression After Transfection In Vitro: Transmitter Responses
J Neurophysiol,
December 1, 2003;
90(6):
3978 - 3985.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. M Fearon, M. Zhang, C. Vollmer, and C. A Nurse
GABA mediates autoreceptor feedback inhibition in the rat carotid body via presynaptic GABAB receptors and TASK-1
J. Physiol.,
November 15, 2003;
553(1):
83 - 94.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Panek, S. Meisner, and P. H. Torkkeli
Distribution and Function of GABAB Receptors in Spider Peripheral Mechanosensilla
J Neurophysiol,
October 1, 2003;
90(4):
2571 - 2580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bertram, J. Swanson, M. Yousef, Z.-P. Feng, and G. W. Zamponi
A Minimal Model for G Protein-Mediated Synaptic Facilitation and Depression
J Neurophysiol,
September 1, 2003;
90(3):
1643 - 1653.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kubota, S. Katsurabayashi, A. J Moorhouse, N. Murakami, H. Koga, and N. Akaike
GABAB receptor transduction mechanisms, and cross-talk between protein kinases A and C, in GABAergic terminals synapsing onto neurons of the rat nucleus basalis of Meynert
J. Physiol.,
August 15, 2003;
551(1):
263 - 276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Cloues and W. A. Sather
Afterhyperpolarization Regulates Firing Rate in Neurons of the Suprachiasmatic Nucleus
J. Neurosci.,
March 1, 2003;
23(5):
1593 - 1604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-B. Gao and A. N van den Pol
Melanin-concentrating hormone depresses L-, N-, and P/Q-type voltage-dependent calcium channels in rat lateral hypothalamic neurons
J. Physiol.,
July 1, 2002;
542(1):
273 - 286.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. G. Bowery, B. Bettler, W. Froestl, J. P. Gallagher, F. Marshall, M. Raiteri, T. I. Bonner, and S. J. Enna
International Union of Pharmacology. XXXIII. Mammalian gamma -Aminobutyric AcidB Receptors: Structure and Function
Pharmacol. Rev.,
June 1, 2002;
54(2):
247 - 264.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bertram, M. I. Arnot, and G. W. Zamponi
Role for G Protein Gbeta gamma Isoform Specificity in Synaptic Signal Processing: A Computational Study
J Neurophysiol,
May 1, 2002;
87(5):
2612 - 2623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-B. Gao and A. N van den Pol
Melanin concentrating hormone depresses synaptic activity of glutamate and GABA neurons from rat lateral hypothalamus
J. Physiol.,
May 15, 2001;
533(1):
237 - 252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Noguchi and H. Yamashita
Adenosine inhibits voltage-dependent Ca2+ currents in rat dissociated supraoptic neurones via A1 receptors
J. Physiol.,
July 15, 2000;
526(2):
313 - 326.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-N. Cui, E. Coderre, and L. P. Renaud
GABAB presynaptically modulates suprachiasmatic input to hypothalamic paraventricular magnocellular neurons
Am J Physiol Regulatory Integrative Comp Physiol,
May 1, 2000;
278(5):
R1210 - R1216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Obrietan and A. van den Pol
GABAB Receptor-Mediated Regulation of Glutamate-Activated Calcium Transients in Hypothalamic and Cortical Neuron Development
J Neurophysiol,
July 1, 1999;
82(1):
94 - 102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. L. Haak
Metabotropic Glutamate Receptor Modulation of Glutamate Responses in the Suprachiasmatic Nucleus
J Neurophysiol,
March 1, 1999;
81(3):
1308 - 1317.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Meijer, K. Watanabe, J. Schaap, H. Albus, and L. Detari
Light Responsiveness of the Suprachiasmatic Nucleus: Long-Term Multiunit and Single-Unit Recordings in Freely Moving Rats
J. Neurosci.,
November 1, 1998;
18(21):
9078 - 9087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. van den Pol, X.-B. Gao, K. Obrietan, T. S. Kilduff, and A. B. Belousov
Presynaptic and Postsynaptic Actions and Modulation of Neuroendocrine Neurons by a New Hypothalamic Peptide, Hypocretin/Orexin
J. Neurosci.,
October 1, 1998;
18(19):
7962 - 7971.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|